摘要
目的 探讨重组人肝再生增强因子 (hALR)对肝纤维化大鼠血清透明质酸浓度的影响。方法 建立四氯化碳中毒性及人血白蛋白免疫损伤性两种大鼠肝纤维化模型。模型完成后予不同剂量hALR( 5 0 μg·kg-1·d、10 μg·kg-1·d)治疗。在不同的时间点留取大鼠血清标本 ,测定透明质酸浓度。结果 在两种模型中hALR治疗组大鼠血清透明质酸浓度在治疗过程中的不同阶段(治疗 1、2个月 )均明显低于模型组 (四氯化碳模型分别为 34 0 .7± 32 .1、2 34 .1± 19.5 ;人血白蛋白模型分别为 366.5± 32 .3、2 87.3± 30 .1)。高剂量hALR组大鼠血清透明质酸浓度 (四氯化碳模型分别为 2 0 3.3± 15 .5、134 .1± 9.8;人血白蛋白模型分别为 2 18.9± 15 .8、14 3.1± 8.7)均明显低于低剂量组 (四氯化碳模型分别为 2 73.3± 13.4、186.6± 11.3;人血白蛋白模型分别为 2 76.1± 2 3.4、198.7± 11.5 )。结论 重组人肝再生增强因子可降低肝纤维化大鼠血清透明质酸含量。
Objective To investigate the effect of re combinant human augmenter of liver regeneration (hALR) on serum hyaluronic acid content in fibrotic rats.Methods CCl_4 and albumin induced two kinds of animal mo dels of rat experimental liver fibrosis were established and different dosages ( 50μ/kg per day,10μ/kg per day) of recombinant hALR were given after the d ev elopment of model.Serum specimens were obtained at different time points of trea tment and hyaluronic acid content was measured by radioimmunoassay (RIA).Results In both rat models of experimental liver fibrosis ,serum hyaluronic acid content in hALR treating group were significantly lower than in the model group (CCl_4 model:340.7±32.1,234.1±19.5;albumin model:366 .5±32.3,287.3±30.1 respectively) in different time points of treatment (treat ing for 1 and 2 months).Serum hyaluronic acid content in high dose hALR treating group (CCl_4 model:203.3±15.5,134.1±9.8;albumin model: 218.9±15.8,143.1± 8.7) were significantly lower than in the low dose hALR treating group (CCl_4 m odel: 273.3±13.4,186.6±11.3;albumin model:276.1±23.4,198.7±11.5).Conclusion Recombinant hALRmay decrease serum hyaluron ic acid content in fibrotic rats.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2001年第6期534-535,共2页
Chinese Journal of Experimental Surgery
